Thomson Reuters, Linguamatics launch solution to advance clinical R&D
The Intellectual Property and Science business of Thomson Reuters, a provider of intelligent information for businesses and professionals, is collaborating with Linguamatics, a U.K.-based provider of text analytics software, to advance pharmaceutical clinical trial R&D with the launch of Cortellis Informatics Clinical Text Analytics for I2E.
The new solution, available through Thomson Reuters Cortellis—an intelligence platform for life science professionals—applies the Linguamatics I2E text mining platform to relevant information to assist researchers in finding actionable insights. The content includes clinical trial information, epidemiology data, literature, press releases and conference proceedings.
Cortellis Informatics Clinical Text Analytics for I2E uses the combination of Linguamatics’ NLP text analytics platform with the largest breadth and depth of integrated clinical content available. Through a single interface, users will be able to glean new insights in support of trials, site selection and competitive intelligence, helping them to design more effective clinical trials and gain a deeper understanding of the implications of their results.
Users will be able to gain greater insights from their data with the combination of state-of-the-art text and high quality, hand curated content offered by Cortellis Informatics Clinical Text Analytics for I2E. Advanced text analytics will allow for rapid extraction and connection of relevant facts and relationships within the content, improving speed to insight. The ability to generate data tables from these resources will support users in preclinical studies, trial design, business intelligence and provide a deeper understanding of the impact of clinical trials. Fast, easy-to-use functionality allows for timely and accurate searches.
Jon Brett-Harris, managing director of Thomson Reuters Life Science business, said, “Our joint solution will make it easier for researchers to obtain the insights they need to help them make decisions that optimize the drug development process.”